PNPLA3 and hepatocellular carcinoma: A longitudinal Asiatic study on a cohort of 1550 patients with histological diagnosis of MASLD, reported that the 5‐year rate of liver‐related events (HCC or hepatic decompensation) progressively increased from 0.5% in patients with PNPLA3 CC genotype, to 3.8% and further to 5.8% in those with CG or GG genotype, respectively, with an adjusted HR of about 16 for patients carrying the at‐risk PNPLA3 rs738409 C > G variant [70].